Seroprevalence of HAV, HBV, HCV, and HEV among acute hepatitis patients at Kenyatta National Hospital in Nairobi, Kenya by Muchiri, I et al.
June 2012 East african MEdical Journal   199
East Africa Medical Journal Vol 89 No. 6 June 2012
SEROPREVALENCE OF HAV, HBV, HCV, AND HEV AMONG ACUTE HEPATITIS PATIENTS AT KENYATTA 
NATIONAL HOSPITAL IN NAIROBI, KENYA
I. Muchiri, BSc, MSc, Medical Virology, Kenya Medical Research Institute, P. O. Box 593, Ruiru, F. A. Okoth, Director, 
Centre for Virus Research, Kenya Medical Research Institute, P. O. Box 54840-00100, Nairobi, J. Ngaira, Jomo Kenyatta 
University of Agriculture and Technology, P. O. Box 62000-00200, Nairobi, S. Tuei, BSc, MSc, Jomo Kenyatta University 
of Agriculture and Technology and Kenya Medical Research Institute, P. O. Box 54840-00100, Nairobi, Kenya.
SEROPREVALENCE OF HAV, HBV, HCV, AND HEV AMONG ACUTE HEPATITIS 
PATIENTS AT KENYATTA NATIONAL HOSPITAL IN NAIROBI, KENYA
I. MUCHIRI, F. A. OKOTH, J. NGAIRA and S. TUEI
ABSTRACT
Background: Acute viral hepatitis is most frequently caused by the hepatitis A virus 
(HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV) and 
hepatitis E virus (HEV). 
Objectives: To determine seroprevalence of HAV, HBV, HCV and HEV among patients 
with acute hepatitis in Nairobi, Kenya, elucidate various risk factors for hepatitis 
viral infection and determine the co-infection rates with these viruses in the acute 
hepatitis patients.
Design:  Across sectional descriptive study.
Setting: Kenyatta National Hospital, from November 2007 to April 2008. 
Subjects: One hundred patients were recruited by purposive sampling method and 
comprised of 57 males and 43 females. 
Results: Among the enrolled patients, twenty three tested positive for one or more 
markers of acute viral hepatitis, that is, HAV, HBV, HCV and HEV. No markers were 
detected in 77 patients, 2% tested positive for IgM anti-HAV; 11% for IgM anti-HBc; 3% 
for HBsAg; 5% for HCV RNA and 7% for IgM anti-HEV.Various risk factors associated 
with acute viral hepatitis were identified; poor sanitation, source of water, occupation, 
place of residence, level of education,household size, drug abuse and sexual behaviours.
Co-infection rate with hepatitis Viruses was at 4%, IgM anti-HAV and IgM anti-HEV 
1 % (n=1); IgM anti-HBc and IgM anti-HEV 1% (n=1); IgM anti-HBc and anti-HCV 
2% (n=2).Three patients were positive for HBsAg; among this two were negative for 
IgM anti-HBc and this accounted for HBV carriage (2 %). 
Conclusion: Hepatitis viruses’ infections are common cause of hepatitis among patients 
with acute hepatitis at Kenyatta National Hospital. Co-infection with these viruses 
was also identified among these patients.
INTRODUCTION
Viral hepatitis is a recognised major public health 
problem worldwide, but more prevalent in developing 
countries. Hepatitis B virus (HBV) and Hepatitis C 
virus (HCV) have received more attention due to their 
wide distribution and high prevalence, and also to 
the severe long-term sequelae of chronic infections 
with these agents, liver cirrhosis and hepatocellular 
carcinoma (3).
 The global distribution of hepatitis B infection 
varies greatly. It is estimated that 350 million people 
globally are chronic carriers of the hepatitis B virus 
of who 170 million reside in Africa. The prevalence 
of HBV carriers varies substantially between regions, 
from 7 to 35 % (22). The wide range is largely related 
to differences in age at the time of infection, a factor 
that is inversely related to the risk of chronic infection. 
In areas where the prevalence is high, such as 
Africa, Southeast Asia and China more than half the 
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population is infected at some time in their lives, and 
more than eight percent are chronic carriers of HBV, 
the result of either neonatal transmission (vertical) or 
transmission from one child to another (horizontal)
(3). Areas with low levels of endemicity include North 
America, Western Europe, and Australia, where only a 
minority of people comes into contact with the virus, 
as a result of horizontal transmission among young 
adults (3).
 The prevalence of serological markers of 
exposure to HBV in sub-Saharan Africa is high, up 
to 90% in many areas (1). In Kenya carrier rate for 
Hepatitis B surface Antigen is between 10 and 15 % 
(8). The prevalence of HBsAg in Nairobi and rural 
Kenya range between 3 to 30 %(16) and at the Kenyan 
coast, 11.4% of the population are positive for HBsAg 
(16). A study on the seroprevalence of hepatitis B virus 
and hepatitis C virus in the regional blood transfusion 
centres of Kenya showed prevalence of HBV and 
HCV to be 3.0 and 0.75% respectively (23).
 Hepatitis C virus (HCV) infects an estimated 
170 million persons worldwide and thus represents 
a global viral pandemic. Egypt has the highest HCV 
prevalence (7, 8, 19, and 23). The use of parenteral 
antischistosomal therapy in Egypt is thought to 
have contributed to thehighprevalence of antibodies 
against HCV in various regions ranging from 6 to 28 
percent (mean, 22 percent) (7). In Kenya, less than 
one percent of the population is positive for HCV 
antibodies (23).In the United States, 1.8 percent of 
the population is positive for HCV antibodies. HCV 
is responsible for 75 to 95% of all post-transfusion 
hepatitis (8, 19, and 23). High prevalence of HCV has 
also been documented in patients with hepatocellular 
carcinoma in Kenya’s Provincial Hospitals (17).
 HAV is present worldwide, and the risk of 
infection is inversely proportional to levels of 
sanitation and personal hygiene (11). Worldwide, an 
estimated 1.4 million cases of acute hepatitis A occur 
annually. Geographic areas can be characterised by 
high (incidence may reach 150 per 100 000 per year.), 
intermediate or low levels of endemicity patterns of 
HAV infection. The levels of endemicity correlate with 
hygienic and sanitary conditions of each geographic 
area (13).
 Hepatitis E virus (HEV) causes epidemics and 
sporadic viral hepatitis, often involving very large 
numbers of patients. Such epidemics have occurred 
in several countries on all continents, although most 
are in tropical and subtropical areas of the world (18). 
Hepatitis E virus is the leading cause of acute viral 
hepatitis in young to middle-aged adults in Asia 
(18). In a study carried out in Cairo, Egypt; HEV 
was found to be a common cause of acute hepatitis 
in a paediatric population occurring in 12% of the 
patients (10). HEV has also been implicated as cause 
of fulminant hepatic failure in India (1).The highest 
prevalence of infection occurs in regions where low 
standards of sanitation promote the transmission 
of the virus. The prevalence of antibody to HEV in 
suspected or documented endemic regions has been 
much lower than expected (3-26%). Screening of 
blood donors in central Europe and North America 
has shown a prevalence of anti-HEV antibodies of 1.4 
- 2.5%, in South Africa of 1.4%, in Thailand of 2.8%, 
in Saudi Arabia of 9.5%, and in Egypt of 24.0% (18).
The prevalence of antibody to HEV in non-endemic 
regions (like the US) has been much higher than 
anticipated (1 - 3%) (18),in Western Europe it is at 5.3 
% (5). In the Asian subcontinent, Hepatitis E is more 
severe than hepatitis A, with mortality rates in the 
range of 1–2%, compared with 0.2% for hepatitis A 
(18).
 Previous prevalence studies of acute viral 
hepatitis in Kenya were carried out by Bagshawe et 
al., in 1972, Greenfield in 1982 and Atina et al., in 2004. 
In The first study, HBsAg was found in 54% of acute 
hepatitis cases at the Kenyatta National Hospital.  The 
second study looked at adults with acute sporadic 
hepatitis at KNH; Hepatitis B virus was responsible 
for 70% of cases, HNANB for 18%, and HAV for only 
12%. The third study looked at patients at least six 
months old with a history of jaundice not exceeding 
six months and Hepatitis A, B, and C accounted for 
41.7, 26.2 and 7.1% of the patients respectively, 13.1% 
of all patients were HBsAg carriers. 
 HEV had not yet been discovered during the first 
studies hence its involvement in acute hepatitis was 
not assessed. HEV has been shown to be a significant 
cause of epidemics and acute sporadic hepatitis in 
the developing countries. HEV has been identified as 
a cause of acute sporadic hepatitis in refugee camps 
in northern Kenya (13); these refugees originate from 
the neighbouring countries like Somalia, Southern 
Sudan and Ethiopia where HEV epidemics have been 
reported (13).
MATERIALS AND METHODS
Study site: This study was carried out at Kenyatta 
National Hospital, a referral hospital in Nairobi after 
approval by the hospital’s Ethical Review Committee 
and the Kenya medical Research Institute/National 
Ethical Review Committee (KEMRI/NERC). After 
collecting specimens from patients in this site, the 
main laboratory work was carried out at the Center 
for Virus Research (CVR), Kenya Medical Research 
Institute, Nairobi.
Study Population: A total of a hundred patients (both 
inpatients and outpatients) were recruited for this 
study by purposive sampling at Kenyatta National 
Hospital’s Medical wards and the Liver clinic between 
November 2007 and April 2008. The patients who 
visit this section of the hospital normally have liver 
diseases of various forms and are normally refered 
SeroprevalenceJune 2012.indd   200 7/30/13   12:42:42 PM
June 2012 East african MEdical Journal   201
Table 1
Demorgraphic Characteristics of Recruited Patients
Gender N (%) Age range(years) Mean age Standard deviation Median
Male 57 19-83 38.95 13.87 34
Female 43 16-78 36.40 14.68 31
here for specialised treatment and care. Subjects 
whose main complaint was consistent with WHO 
recommended case definition of acute hepatitis were 
enrolled into the study (25).
Questionnaire: Health history and lifestyle/
demographic questionnaires were administered to 
all subjects by the clinician attending to the patient 
at the study sites. All the patients were interviewed 
to identify risk factors for hepatitis during the 
six months preceding the onset of illness.The 
questionnaires included: a detailed assessment of 
the patient health history; patient demographics; 
age, sex; social and economic lifestyle; occupation 
and place of residence.
Specimen collection: The attending clinician or a 
phlebotomist drew five millilitres of blood from 
all enrolled patients which was transported to the 
laboratory immediately. The specimens were kept 
at temperature of 0ºC to 4ºC in ice packs until they 
got to the laboratory where the serum was separated 
from the red blood cells by centrifugation at 10000 
rpm for ten minutes (KUBOTA KS-5000) and stored 
at -20°C in a freezer until processed.
Specimen processing: The blood was screened for 
HAVIgM antibody by ELISA method; hepatitis 
B surface antigen by an inhouse method,HBsAg 
reverse passive haemagglunation test and hepatitis 
B core antigenIgM antibody by ELISA method; 
total antibody against HCV (anti-HCV) by ELISA 
method and HCV-RNA by RT-PCR method; HEVIgM 
antibody by ELISA method. The laboratory tests 
were aimed at detecting these viral markers in the 
collected specimens.
Data management and Statistical analysis: All 
questionnaire data and laboratory serological tests 
results data were entered into a computer using 
Microsoft Accessand Microsoft excel programmes 
respectively. Prevalence and 95% confidence intervals 
(C.Is) were calculated using standard equations.
 Frequency distributions and risk factors 
association were compared by the use of the 
Pearson chi-square test. P-values of less than 0.05 
were considered to be statisticallysignificant. Data 
analysis was carried out using SPSS 11.5 computer 
software.
Ethical considerations: Authorisation to carry out this 
study was obtained from the Board of Postgraduate 
studies of Jomo Kenyatta University of Agriculture 
and Technology (JKUAT) and Kenya Medical 
Research Institute/NationalEthical Review Committee 
(KEMRI/NERC), the study Protocol was approved 
by the Ethical Review Committees of KNH. Informed 
consent and incase of minors assent were obtained 
from the patients before they were enrolled into the 
study.
RESULTS
Prevalenceof Hepatitis Viruses: A total of 100 patients, 
57 males and 43 females were recruited into the study. 
The age range was 16 years to 83 years; 19 to 83 years in 
males and 16 to 78 years in females, with a mean of 38.95 
years and 36.40 years, standard deviation of 13.87 and 
14.68, and median of 34 and 31 respectively (Table 1).
 Among the enrolled patients, twenty-three 
tested positive for one or more markers of acute 
viral hepatitis, that is, HAV, HBV, HCV and HEV. 
No markers were detected in 77 patients. Two 
patients (2%) tested positive for IgM anti-HAV; 
Three patients (3 %) tested positive for HBsAg; 
11 (11%) tested positive for IgM anti-HBc; Five 
patients(5%) tested positive for HCV RNA (seven 
tested positive for anti-HCV antibody(this were 
confirmed using RT-PCR for HCV but only five 
tested positive for HCV RNA) and seven patients 
(7%) tested positive for IgM anti-HEV (Figure 1).
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Figure 1
Seroprevalence of viral markers in acute hepatitis
The seven samples positive for HCV total antibodies were ran through a confirmatory test using a molecular 
diagnostic test. Five among them turned positive for HCV RNA (Table 2).
Table 2
Prevalence of viral hepatitis in acute hepatitis
Virus markers Positive N (%) Negative N (%)
HBV 13 (13) 87 (87)
HEV 7 (7) 93 (93)
HCV RNA 5 (5) 95 (95)
HAV 2 (2) 98 (98)
Co-infection rate of hepatitis viruses: Four patients tested 
positive for more than one marker of acute infection 
of hepatitis virus (Table 3). One had IgM anti-HAV 
and IgM anti-HEV; one had IgM anti-HBc and IgM 
anti-HEV; and two had IgM anti-HBc and anti-HCV; 
two patients had the HBsAg with negative IgM anti-
HBc.Out of the three patients positive for HBsAg, two 
were negative for IgM anti-HBc antibody and this 
accounted for HBV carriage, which is 2% carriage. 
Table 3
Co-infection rate with hepatitis viruses
Co-infection Frequency(n) Percent (%)
HAV + HEV  1 1
HBV + HEV  1 1
HBV+ HCV  2 2
HAV  1 1
HBV  10 10
HCV  3 3
HEV  5 5
TOTAL  23 77 (Non Reactive)
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Risk Factors
Source of water: the source of household water had an 
influence on the infectivity with HAV; those without 
tap water inside the house n=33 (42.9%)had a greater 
probability of being infected than those that had tap 
water inside the house n=17 (22.1 %). This difference 
was statistically significant (p=0.024).
Type of toilet: the type of toilet used by the study 
participants influenced the infectivity, although 
the association is not statistically significant. Those 
positive for IgM anti-HAV and IgM anti-HEV all 
used pit latrines in their homes (p=0.055), only 
n=7 (63.6%), (p=0.065)and n=3(60%), (p>0.05)of 
those positive for IgM anti-HBc and HCV RNA 
respectively used pit latrines.
Blood and blood product transfusion: Among those 
positive for IgM ant-HBc, n=6 (54.5 %) (p=0.054) had 
had blood/blood product transfusion during the six 
months preceeding the infection.
Sexual behaviours: Some of those positive for IgM 
anti-HBc and HCV-RNA had same sex partners, 
however the association is not statistically significant, 
n=1(9.1%), p=0.067 and n=1 (25 %) p>0.05 respectively 
and also multiple sex patners, n=1 (9.1 %) and n=1 
(25%) respectively.
Intravenous drug use (IVDU): One of the patients 
positive for IgM anti-HBc admitted to have abused 
IV drugs, the association is however not statistically 
significant (p>0.05).
Occupation: most of the patients enrolled into the study 
were non-skilled or semi-skilled however there was 
no statistically significant relation between infectivity 
and the occupation of the patient (p=0.069).
HIV co-infection: In the questionnaires the participants 
had been asked if they had been tested for HIV, only 
57 responded and n=18 (31.5 %) p>0.05were positive. 
Among those positive for HIV, n=1 (6.7%) p>0.05were 
positive for HBV, n=3 (5.6%) p>0.05 were positive for 
HBsAg, n=2 (5.6%) p>0.05 were positive for HCV and 
n=2 (11.1%) p>0.05 were positive for HEV.
DISCUSSION
Prevalence of Hepatitis viruses: Hepatitis B was the 
leading cause of acute hepatitis overall, accounting 
for 13% of all patients enrolled in the study. This is 
comparable to rates reported from other parts of the 
developing world (6, 19). There was a marked decrease 
in prevalence of acute hepatitis B from the 29.9% Atina, 
et al; found in 2004 among patients above 15 years of 
age. With onlya few variable set collected and a small 
patient sample size, it is not possible to hypothesise 
with certainity that various interventions, such as past 
vaccination or health promotion campaigns, had an 
impact on the hepatitis B.  Vaccination programme 
has been implemented for infants; assessment of 
such interventions would require an additional set 
of variables to be collected over a period that include 
the pre-intervention period.
 Acute hepatitis E was the second most common 
type of hepatitis  affecting 7 % (n=7) of all patients. 
This is proportionate to rates reported from other parts 
of the developing world like Taiwan and China at 3 
to 26% (1), but slightly lower than other studies, 12 
% in Egypt (10). The reason for this variations could 
be that the subjects in this study were 12 years and 
above whereas the other studies included all ages.
The prevalence of antibody to HEV in suspected 
or documented endemic regions has been found to 
be 3 - 26% (1, 5) and in non-endemic region it was 
found to be between 1-36% (21). Acute hepatitis E is 
a childhood illness in the developing world because 
it is mainly spread via the oral faecal route and this 
age group may be unable to maintain good hygiene 
standards.In Cairo, Egypt HEV has been found to 
be a common cause of acute hepatitis in a paediatric 
population occurring in 12% of the patients (10).
 The prevalence of hepatitis C was 5%(n=5) 
which is less than what Atina et al., reported in 2004, 
they found the seroprevalence of HCV to be 7.1%. 
The reason for the difference could be that a more 
specific analytical methods were used in this study, 
that is, a fourth generation Elisa kit for HCV and a 
molecular technique(RT-PCR) for HCV. However, 
these findings are comparable with figures reported 
from other part of the world, 4.4% in the USA (3), 
5.4% in Malaysia (19), 9.9% reported in China (24) 
and 10.3% in Japan (25). Ethiopia and Egypt have 
much higher hepatitis C prevalence of 19 and  22% 
respectively, this is attributed to the use of parentral 
anti-schistosomiasis drugs in Egypt (7).
 The prevalence of hepatitis A was found to be 
2%. Studies from other parts of the world have found 
hepatitis A to account for between 3.6 and 66.4% 
of overall acute sporadic hepatitis (3, 6, 19, 24, 25). 
However, these results differ from that found by 
Atina et al., 2004 (7), where hepatitis A was the leading 
cause of acute icteric hepatitis accounting for 41.7% 
of all the acute hepatitis patients. The reason for the 
difference is probably because the participant enrolled 
in this study were aged 12 years and above whereas 
in the previous study children below 12 years were 
included. Hepatitis A is more of a childhood illness 
than adult where in most cases it is as symptomatic, 
hence a number of young (<12 years) probable 
subjects were excluded from this study. HAV is 
spread oral faecally and the young are less likely to 
maintain good personal hygiene standards. Increasing 
awareness of the infectious diseases and improved 
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hygiene standards may also have resulted in the 
decreased prevalence. These results vary from those 
of the developed countries where its been found that 
hepatitis A is an adulthood illness (11), the patients 
are also more affluent  and in some cases having just 
returned from holiday in endemic regions.
Risk factors: Although the prevalence of the 
hepatitis viral markers did not vary with the age 
of the participants and also between the genders 
of the participants in this study, other studies have 
demonstrated variations (14). Young adults (18 to 39 
years of age) are at increased risk for HBV infection; 
this increase is attributed to the greater likelihood of 
multiple sex partners, illicit injection of drugs, and 
other high-risk behaviours in this age group than in 
others (14).
 Blood and blood product transfusion; this study 
demonstrated an association between HBV and blood 
transfusion although not statistically significant, 
p=0.054. HBV and HCV are both transmitted through 
the blood and by sexual contact. Infection with both 
viruses is frequent, particularly in areas where the 
two viruses are endemic and among people at high 
risk for parenteral infections (2).
 There was a difference in infectivity with HEV 
between those without tap water inside the house 
and those that had tap water inside the house. This 
difference was statistically significant (p=0.024). 
Hepatitis E virus (HEV) has been identified as 
responsible for massive waterborne epidemics of 
acute hepatitis in Asia, and also in Sudan and Iraq 
(11).
 The type of toilet used by the study participants 
influenced the infectivity although not statistically 
significant. Those positive for IgM anti-HAV and 
IgM anti-HEV all used pit latrines in their homes. 
Infections with HAV and HEV occur early in life in 
areas where sanitation is poor and living conditions 
are crowded (11), since transmission of the viruses 
is through the faecal oral route.
Co-Infection rates with Hepatiti Viruses: The prevalence 
of HbsAg was 3%(2), and 2% were positive for HbsAg 
but negative for IgM ant-HBc. This indicates persistent 
HBV infection and which accounted for HBV carriage, 
this is lower than what was reported by Okoth and 
others, it was reported at between 5-15% in Nairobi 
province of Kenya (17) and at 13.1% reported by 
Atina and others (4). Globally,Carriage vary from 8 
to 53% (6, 9, 19).
 Co-infection rate with  hepatitis virus among 
acute hepatitis patients was 4%,Four patients tested 
positive for more than one marker of acute infection 
with hepatitis viruses. One had IgM anti-HAV and 
IgM anti-HEV (1%); one had IgM anti-HBc and IgM 
anti-HEV (1%); and two had IgM anti-HBc and anti-
HCV antibodies (andHCV-RNA) (2%). Co-infection 
with Hepatitis viruses causes a more severe acute 
hepatitis than that caused by either of these viruses 
alone and may develop to fulminant infection that 
is more severe and deadly (2). Co-infection with 
Hepatitis B virus and Hepatitis C virus is possible 
because of the shared transmission route; co-infection 
in intravenous drug users accelerates the clinical 
progression of both hepatitis B and hepatitis C (2).
Co-infection of children with HAV andHEV is high 
because both viruses are transmitted mainly through 
the faecal oral route (11).
 Co-infection of Hepatitis viruses with HIV, 
among those positive for HIV; 0% was positive for 
HAV, 6.7 %( n=1) were positive for HBVIgM, 5.6 
% (n=3) were positive for HBsAg, 5.6% (n=2) were 
positive for HCV and 11.1% (n=2) were positive 
for HEVIgM. These infection rates among the HIV 
patients are high compared to the HIV negative 
patients and demonstrate a higher susceptibility of 
the HIV positive persons to hepatitis virus infection 
than the general population. There was an association 
between HIV and hepatitis virus infection however 
it is not statistically significant (p>0.05). An earlier 
study at Kenyatta National Hospital had shown HIV/
HAV, HIV/HBV and HIV/HCV co-infection rates at 
19.2, 22.7 and 0 % respectively (4). A South African 
study found HIV/HBV and HIV/HCV co-infection 
rates of 41% and 1% respectively (15). In Tanzania 
co-infection rate of HIV/HBV and HIV/HCV was 
found to be 1.2 and 13.8% respectively (20).
In conclusion, in this study, Hepatitis viruses were 
identified as important aetiological agents of acute 
hepatitis with a prevalence rate of 2, 11, 5 and 7% for 
HAV, HBV, HCV and HEV respectively, 77% were 
non-reactive for any of the hepatitis viruses. 
Various risk factors associated with acute viral 
hepatitis were identified, for example;sanitation, 
source of water, drug abuse and sexual behaviours. 
Co-infection rate with hepatitis virus was at 4%; 
IgM anti-HAV and IgM anti-HEV 1 % (n=1); IgM 
anti-HBc and IgM anti-HEV 1% (n=1); IgM anti-HBc 
and anti-HCV 2% (n=2), and HbsAg carriage rate 
was at 2%.
Recommendations: the findings in this study may be 
an underestimate of the true prevalence of hepatitis 
viruses since not all infected persons have persistent 
serological evidence of infection. HAV, HBV and 
HEV IgM antibodies levels in infected patients’ blood 
decreases gradually overtime. Hence timing of blood 
specimen collection at clinical symptoms onset is 
paramount, this can be achieved by conducting senitel 
surveillance studies at various health facilities.
HIV positive patients may have a higher rate of 
infection with the Hepatitis viruses as shown in 
this study and other studies carried out elsewhere, 
hence a further study is important to determine the 
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